← SynDRA
INFIGRATINIB
SynDRA canonical compound SYN0027902 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Approval status | Approved · OTC |
|---|
| Primary target(s) | FGFR4 |
|---|
| Mechanism of action | FGFR inhibitor |
|---|
All known targets
- FGFR1
- FGFR2
- FGFR3
- FGFR4
- KDR
- ROS1
- MET
- MST1R
- NTRK2
- PDGFRA
- RET
- SRC
Mechanisms of action (all sources)
- FGFR inhibitor
- FGFR3 INHIBITOR
- Fibroblast growth factor receptor inhibitor
- FGFR1 INHIBITOR
- FGFR4 INHIBITOR
- FGFR2 INHIBITOR
- KDR INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AKT1
- PIK3CD
- MAPKAPK5
- MERTK
- MKNK1
- MKNK2
- MTOR
- NEIL1
- NEIL2
- NTHL1
- PAK2
- PDK1
- PI4KB
- PIK3C3
- PIK3CA
- PIK3CB
- PIM2
- AURKA
- PKN1
- PKN2
- PLK1
- PRKACA
- PRKCA
- PRKCQ
- PTK2
- ROCK2
- RPS6KA1
- SMUG1
- STK38L
- TDG
- UNG
- WNK1
- MAPKAPK2
- MAPK9
- MAPK14
- MAPK12
- AXL
- BTK
- CAMK2A
- CAMK2B
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ALAT2
- BCR
- CP2C9
- CP3A7
- KSYK
- NR1I3
- VGFR2
Drug classes
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- TRUSELTIQ
- Truseltiq
- infigratinib phosphate
- truseltiq
- BGJ-398
- NVP-BGJ398
- BGJ398
- BGJ398 (NVP-BGJ398)
- BGJ398 (NVP-BGJ398
- INFIGRATINIB)
- INFIGRATINIB (BGJ398)
- KIN001-271
- MVP-BGJ398
- A4055ME1VK
- BGJ 398
- CHEBI:63451
- infigratinibum
- RefChem:58155
- DTXCID70158729
- Infigratinib [INN]
- Infigratinib free base
- Infigratinib (BGJ398)
- MFCD22123241
- Infigratinib [USAN]
- BGJ 398; Infigratinib; NVP-BGJ 398
- UNII-A4055ME1VK
- C26H31Cl2N7O3
- Infigratinib (USAN/INN)
- Infigratinib [USAN:INN]
- NVP-BGJ398(Infigratinib)
- MLS006010953
- INFIGRATINIB [WHO-DD]
- SCHEMBL374435
- NVP-BGJ398(Infigratinib)?
- GTPL7877
- orb1306898
- EX-A057
- YQF2818
Look up INFIGRATINIB in the interactive SynDRA portal →